Development of immunity-related adverse events correlates with baseline clinical factors, survival and response to anti-PD-1 treatment in patients with inoperable or metastatic melanoma.
Melanoma
anti-PD-1 therapy
immune-related adverse events
immunotherapy
irAE
Journal
The Journal of dermatological treatment
ISSN: 1471-1753
Titre abrégé: J Dermatolog Treat
Pays: England
ID NLM: 8918133
Informations de publication
Date de publication:
Jun 2022
Jun 2022
Historique:
pubmed:
1
6
2021
medline:
7
7
2022
entrez:
31
5
2021
Statut:
ppublish
Résumé
The relationship between immune related adverse events (irAEs) and efficacy is not definitively proven, and data on the relationship between irAE and treatment efficacy are contradictory. Five hundred ninety-three consecutive patients with unresectable or metastatic melanoma treated in the first line with anti-PD-1 (nivolumab or pembrolizumab) between January 2016 and December 2019 were enrolled in the study. Statistically significant differences were demonstrated between the group of patients without and with irAE in median OS and PFS ( The occurrence of irAE was associated with longer OS, PFS, and more frequent response to treatment. IrAE occurred statistically significantly more often in patients with mucosa primary tumor, with normal LDH levels, without brain metastases, stages III, M1a, and M1b.
Sections du résumé
BACKGROUND
UNASSIGNED
The relationship between immune related adverse events (irAEs) and efficacy is not definitively proven, and data on the relationship between irAE and treatment efficacy are contradictory.
MATERIAL AND METHODS
UNASSIGNED
Five hundred ninety-three consecutive patients with unresectable or metastatic melanoma treated in the first line with anti-PD-1 (nivolumab or pembrolizumab) between January 2016 and December 2019 were enrolled in the study.
RESULTS
UNASSIGNED
Statistically significant differences were demonstrated between the group of patients without and with irAE in median OS and PFS (
CONCLUSION
UNASSIGNED
The occurrence of irAE was associated with longer OS, PFS, and more frequent response to treatment. IrAE occurred statistically significantly more often in patients with mucosa primary tumor, with normal LDH levels, without brain metastases, stages III, M1a, and M1b.
Identifiants
pubmed: 34057374
doi: 10.1080/09546634.2021.1937477
doi:
Substances chimiques
Nivolumab
31YO63LBSN
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM